Is MOTS-c FDA approved?
No. The FDA took it off its Category 2 compounding list in April 2026. In July 2026 an advisory panel voted 7 to 5 to recommend it for compounding anyway, against the FDA reviewers' own advice. One mid-stage study (NCT07505745) was signing people up as of this site's latest review. It would be the first careful study that gives it to people as a drug.
Every FDA-approved compound in the archive, as a list
Studies in people from the compound pages this answer belongs to
- MOTS-c
- A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c 2021 PMID 33468709
- Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition 2020 PMID 32182209
- Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction 2018 PMID 29242099
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of immune and longevity peptides. Thymosin alpha-1, thymalin, epitalon, MOTS-c, humanin, and the bioregulator family.